1. Home
  2. EDIT vs GUG Comparison

EDIT vs GUG Comparison

Compare EDIT & GUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

N/A

Current Price

$1.63

Market Cap

422.3M

Sector

Health Care

ML Signal

N/A

Logo Guggenheim Active Allocation Fund of Beneficial Interest

GUG

Guggenheim Active Allocation Fund of Beneficial Interest

N/A

Current Price

$13.58

Market Cap

462.7M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
EDIT
GUG
Founded
2013
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
422.3M
462.7M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
EDIT
GUG
Price
$1.63
$13.58
Analyst Decision
Buy
Analyst Count
13
0
Target Price
★ $6.10
N/A
AVG Volume (30 Days)
★ 2.2M
95.8K
Earning Date
11-09-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 37.50
N/A
EPS
N/A
★ N/A
Revenue
★ $31,937,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 132.64
N/A
52 Week Low
$1.66
$13.55
52 Week High
$3.94
$16.46

Technical Indicators

Market Signals
Indicator
EDIT
GUG
Relative Strength Index (RSI) 29.08 36.98
Support Level N/A $13.55
Resistance Level $3.00 $16.11
Average True Range (ATR) 0.21 0.22
MACD -0.09 -0.03
Stochastic Oscillator 1.10 5.83

Price Performance

Historical Comparison
EDIT
GUG

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

About GUG Guggenheim Active Allocation Fund of Beneficial Interest

Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The Fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The Fund represents a single operating segment. Its products are Mutual Funds, Wealth Management SMAS, Institutional SMAS, ETFS, UITS, UCITS, CIT, Closed-End Funds, Private Funds, Rydex Funds, and Variable Insurance Funds.

Share on Social Networks: